US pharmaceutical company Eli Lilly has decided to suspend investments and new clinical trials in Russia, as well as the export of a number of drugs to the country. The corresponding decision follows from a statement published on the company’s website.

“We have suspended all investments, promotional activities and new clinical trials in Russia, as well as the export of non-essential medicines to this country. Our activities in Russia are now focused only on ensuring that people suffering from diseases such as cancer and diabetes continue to receive the Lilly medicines they need,” the statement reads.

In addition, the company intends to donate all profits from sales in Russia to humanitarian aid organizations.

Eli Lilly produces medicines for cancer and diabetes patients and is the world’s leading producer of insulin. It was the first foreign pharmaceutical company to announce that it would stop supplying certain medicines to Russia.